VistaGen Therapeutics (VTGN)
NASDAQ:VTGN
Want to see VTGN full AI Analyst Report?
Top Page
VistaGen Therapeutics
(NASDAQ:VTGN)
Select Model
Select Model
Rating:50Neutral
Price Target:
$0.69
▲(9.52% Upside)
Action:Reiterated
Date:06/17/26
The score is primarily held down by weak financial performance—deepening losses and significant cash burn—despite low leverage. Technicals provide some near-term support (price above key short-term averages, RSI moderately strong), while valuation remains constrained by negative earnings and no dividend. Clinical/program updates and a cautiously neutral earnings-call posture modestly help, but uncertainty around efficacy interpretation, regulatory path, and governance compliance keeps the overall score in the mid range.
Positive Factors
Late‑stage program execution (PALISADE trials)
Completion of PALISADE‑4's randomized portion and prior PALISADE‑3 progress materially reduces near‑term execution risk versus earlier stages. Sustained on‑track enrollment and trial completion increase the likelihood of clearer efficacy signals and enable timely regulatory dialogue and potential NDA planning.
Negative Factors
High cash burn and widening losses
Material and accelerating cash burn and widening net losses indicate the company remains heavily reliant on external financing. Persistent negative operating and free cash flow erode equity, pressure runway, and raise dilution and refinancing risk, constraining strategic flexibility over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Late‑stage program execution (PALISADE trials)
Completion of PALISADE‑4's randomized portion and prior PALISADE‑3 progress materially reduces near‑term execution risk versus earlier stages. Sustained on‑track enrollment and trial completion increase the likelihood of clearer efficacy signals and enable timely regulatory dialogue and potential NDA planning.
Read all positive factors
VistaGen Therapeutics (VTGN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$27.50M
Dividend YieldN/A
Average Volume (3M)1.23M
Price to Earnings (P/E)―
Beta (1Y)0.81
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees48
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.87
Shares Outstanding41,032,450
10 Day Avg. Volume1,055,596
30 Day Avg. Volume1,225,812
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)0.61
Price to Sales (P/S)17.15
P/FCF Ratio-0.33
Enterprise Value/Market Cap-0.26
Enterprise Value/Revenue-5.62
Enterprise Value/Gross Profit-13.66
Enterprise Value/Ebitda0.10
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-1.1
Revenue Forecast (FY)$500.00K
VistaGen Therapeutics Business Overview & Revenue Model
Company Description
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical entity dedicated to advancing and commercializing innovative medications for anxiety, depression, and various other disorders impacting the central nervous system (CNS). A key compo...
How the Company Makes Money
VistaGen’s business model is primarily that of a clinical-stage drug developer. As such, it has historically generated little to no recurring revenue from product sales because its lead drug candidates have been in clinical development rather than...
VistaGen Therapeutics Earnings Call Summary
Earnings Call Date:Feb 12, 2026
(Q3-2026)
| % Change Since: |
Next Earnings Date:Aug 06, 2026
Earnings Call Sentiment Neutral
The call presented a balanced mix of progress and uncertainty. Positive elements include completion of PALISADE-3 randomized portion, PALISADE-4 enrollment on track, active open-label extensions, focused operational improvements, an AI/ML-driven analytic program, USAN adoption of refisolone with an IND planned in H1 2026, and $61.8M in reported cash with cost-control measures. Negative elements center on a higher placebo response in PALISADE-3 that necessitates additional analysis and operational remediation, unresolved efficacy clarity from top-line data, potential SAP modifications that would require FDA resubmission, reliance on exploratory AI/ML methods with no guarantees, and limited disclosure on financial runway timing. Given the roughly balanced number of material positives and material uncertainties, the overall tone is cautiously neutral.Positive Updates
Completion of PALISADE-3 Randomized Portion
The company completed the randomized portion of the PALISADE-3 Phase III trial in social anxiety disorder as guided and is analyzing results to inform PALISADE-4 and broader program strategy.
Negative Updates
Higher Placebo Response in PALISADE-3
Management acknowledged a notably higher placebo response in PALISADE-3 relative to PALISADE-2, which prompted retraining and operational changes and necessitates deeper analysis to understand drivers of the effect.
Read all updates
Q3-2026 Updates
Positive
Negative
Completion of PALISADE-3 Randomized Portion
The company completed the randomized portion of the PALISADE-3 Phase III trial in social anxiety disorder as guided and is analyzing results to inform PALISADE-4 and broader program strategy.
Read all positive updates
Company Guidance
On the FY2026 Q3 call (quarter ended December 31, 2025), management reiterated that the randomized portion of PALISADE‑3 is complete and PALISADE‑4 is ongoing and on track (enrollment continuing as planned after the Dec. 17 announcement), with the SAP already submitted/locked for the study (any changes would require FDA resubmission prior to database lock) and top‑line results to follow after last patient/last visit; open‑label extensions continue (using LSAS and SPIN), AI/ML analyses across PALISADE‑1/2/3 are underway to identify covariates that might inform SAP modifications and regulatory strategy, and PALISADE‑2 plus a successful PALISADE‑4 could support an NDA. Financially, the company reported $61.8 million in cash, cash equivalents and marketable securities as of 12/31/25, 39.7 million shares outstanding (42.0 million weighted‑average for the quarter), has implemented company‑wide cash‑preservation measures to extend runway, and plans a U.S. IND submission for refisolone (PH80) in H1 2026.VistaGen Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
64
Positive
Cash Flow
22
Negative
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.27M | 486.00K | 1.06M | -227.00K | 1.11M |
| Gross Profit | 1.27M | 486.00K | 1.06M | -227.00K | 1.11M |
| EBITDA | -71.39M | -50.78M | -28.79M | -58.74M | -47.05M |
| Net Income | -69.69M | -51.42M | -29.36M | -59.25M | -47.76M |
Balance Sheet | |||||
| Total Assets | 48.56M | 84.34M | 123.65M | 21.09M | 74.64M |
| Cash, Cash Equivalents and Short-Term Investments | 45.40M | 80.48M | 119.17M | 16.64M | 68.14M |
| Total Debt | 1.04M | 1.51M | 2.12M | 2.71M | 3.04M |
| Total Liabilities | 13.04M | 13.95M | 9.37M | 9.01M | 9.93M |
| Stockholders Equity | 35.52M | 70.39M | 114.29M | 12.08M | 64.72M |
Cash Flow | |||||
| Free Cash Flow | -66.44M | -42.29M | -25.87M | -49.93M | -45.46M |
| Operating Cash Flow | -66.44M | -42.10M | -25.81M | -49.72M | -45.26M |
| Investing Cash Flow | -877.00K | -13.15M | -61.00K | -740.00K | -200.40K |
| Financing Cash Flow | 30.97M | 3.21M | 128.40M | -1.04M | 10.48M |
VistaGen Therapeutics Technical Analysis
Positive
0.63
Price Trends
0.61
Positive
0.59
Positive
1.85
Negative
Market Momentum
<0.01
Negative
60.27
Neutral
82.13
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VTGN, the sentiment is Positive. The current price of 0.63 is above the 20-day moving average (MA) of 0.61, above the 50-day MA of 0.61, and below the 200-day MA of 1.85, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 60.27 is Neutral, neither overbought nor oversold. The STOCH value of 82.13 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VTGN.
VistaGen Therapeutics Risk Analysis
VistaGen Therapeutics disclosed 93 risk factors in its most recent earnings report. VistaGen Therapeutics reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
VistaGen Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | $132.02M | 8.57 | 35.58% | ― | 93.50% | ― | |
53 Neutral | $241.62M | -3.53 | -41.31% | ― | ― | 73.45% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $27.50M | -0.37 | ― | ― | ― | ― | |
48 Neutral | $423.67M | -6.93 | -22.51% | ― | 1199.64% | 30.81% | |
47 Neutral | $262.52M | -3.72 | -147.80% | ― | 1.97% | -25.03% | |
45 Neutral | $269.94M | -0.74 | 309.79% | ― | -35.61% | -68.92% |
* Healthcare Sector Average
VTGN
VistaGen Therapeutics
0.67
-1.33
-66.50%
MGNX
MacroGenics
4.13
2.82
215.27%
OVID
Ovid Therapeutics
2.27
1.96
632.26%
SPRO
Spero Therapeutics
2.28
-0.74
-24.50%
IKT
Inhibikase Therapeutics
1.83
0.17
10.24%
SRZN
Surrozen
23.25
13.26
132.73%
VistaGen Therapeutics Corporate Events
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
VistaGen Reaches Key Safety Milestone for Fasedienol Program
Positive
Jun 9, 2026
On June 9, 2026, Vistagen announced that its clinical program for fasedienol nasal spray for the acute treatment of social anxiety disorder has reached, and is estimated to exceed, minimum patient exposure levels recommended under ICH E1 safety gu...
Business Operations and StrategyExecutive/Board Changes
VistaGen Appoints New Chief Medical Officer to Advance Pipeline
Positive
May 19, 2026
Vistagen Therapeutics (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company focused on neuroscience, leveraging nose-to-brain neurocircuitry to develop intranasal product candidates known as pherines. Its pipeline includes fasedienol i...
Business Operations and StrategyProduct-Related Announcements
VistaGen Reports Positive Long-Term Data for Fasedienol
Positive
May 12, 2026
On May 12, 2026, Vistagen reported preliminary positive data from the ongoing open-label extension of its PALISADE-3 Phase 3 trial evaluating intranasal fasedienol for the acute treatment of social anxiety disorder. In 341 adults using as-needed d...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
VistaGen Completes Phase 3 PALISADE-4 Trial Milestone
Positive
May 8, 2026
On May 8, 2026, Vistagen announced that the last patient completed the last visit in the randomized, double-blind, placebo-controlled portion of PALISADE-4, its U.S. multi-center Phase 3 public speaking challenge study of fasedienol nasal spray fo...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
VistaGen Advances Refisolone Nasal Spray in U.S. Phase 2
Positive
Apr 28, 2026
On April 22, 2026, Vistagen announced it received an FDA “Study May Proceed” letter under its U.S. IND for refisolone nasal spray, a non-hormonal, non-systemic Phase 2 candidate for treating moderate to severe menopausal vasomotor symp...
Business Operations and StrategyExecutive/Board Changes
VistaGen Therapeutics Grants Broad Employee Retention Stock Options
Positive
Apr 13, 2026
On April 7, 2026, Vistagen Therapeutics’ compensation committee approved broad-based retention awards in the form of stock options for all employees, including 75,000-share option grants to five senior executives. The options, issued under t...
Executive/Board ChangesRegulatory Filings and Compliance
VistaGen Faces Nasdaq Audit Committee Compliance Setback
Negative
Apr 2, 2026
On April 1, 2026, VistaGen Therapeutics, Inc. notified Nasdaq that it had fallen out of compliance with Nasdaq Listing Rule 5605(c)(2) after director Mary Rotunno’s resignation that day reduced its Audit Committee from three independent memb...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.